Kevin F. Staveley-O’Carroll

Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.

K Y Lin, Frank Guarnieri, Kevin F. Staveley-O’Carroll et al. · PubMed · 1996 · 1K citations

Medicine, Immunology, Oncology +17

Induction of antigen-specific T cell anergy: An early event in the course of tumor progression

Kevin F. Staveley-O’Carroll, Eduardo M. Sotomayor, Jami Montgomery et al. · Proceedings of the National Academy of Sciences · 1998 · 696 citations

Life Sciences, Immunology, Oncology +17

Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens.

T.‐C. Wu, Frank Guarnieri, Kevin F. Staveley-O’Carroll et al. · Proceedings of the National Academy of Sciences · 1995 · 347 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Cross-presentation of tumor antigens by bone marrow–derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression

Eduardo M. Sotomayor, Ivan Borrello, Frédérique‐Marie Rattis et al. · Blood · 2001 · 208 citations · Full text

Life Sciences, Immunology, Oncology +17

Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity

Hyam I. Levitsky, Joel M. Montgomery, Mojgan Ahmadzadeh et al. · The Journal of Immunology · 1996 · 181 citations · Full text

Medicine, Immunology, Oncology +17